IGFBP3 and colorectal carcinoma: Although there is a consensus of increased serum IGF1 and reduced IGFBP3 levels in CRC patients, thus increasing IGF1 availability and its mitogenic power67–69, a similar Egyptian report demonstrated reduced levels of serum IGF1 in overall CRC patients and average weight and overweight/obese CRC patients compared with their corresponding controls36.